

IXCHIQ is the first single-dose vaccine for prevention against chikungunya in adults who are at increased risk of exposure to CHIKV¹

Chikungunya is a potentially life-altering mosquito-borne disease. Of people infected, ~43% do not recover from the acute phase of a chikungunya infection and have debilitating consequences that last for months or years.^{2,3,4}

Mosquito-borne chikungunya has been found in
over 110 countries^{2,5}



Consider a traveler's risk for CHIKV during your next pretravel health consultation



Frequent travelers for chikungunya-endemic areas



People moving to chikungunya-endemic countries



Long-term travelers



Short-term travelers with increased risk based on planned activity and time of travel



Spontaneous travelers with unplanned itineraries

INDICATION

IXCHIQ is a vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.

This indication is approved under accelerated approval based on anti-CHIKV neutralizing antibody levels. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory studies.

Please see Important Safety Information on the next page and full [Prescribing Information](#).

With IXCHIQ, the power of prevention is at your fingertips



Strong seroresponse rate^{1,6}



Convenient single dose¹



Established safety profile^{1,6}



*In a double-blind, prospective, phase 3 study of 4,115 adults 18 years and over at 28 days post vaccination.⁶

For more information, visit IXCHIQhcp.com

IMPORTANT SAFETY INFORMATION

Contraindications

Do not administer IXCHIQ to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy (e.g., from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised), or to individuals with a history of a severe allergic reaction to any component of the vaccine.

Warnings and Precautions

Appropriate medical treatment used to manage immediate allergic reactions must be available in the event an acute anaphylactic reaction occurs following administration of IXCHIQ.

Vaccination with IXCHIQ may cause severe or prolonged chikungunya-like adverse reactions. Severe chikungunya-like adverse reactions that prevented daily activity and/or required medical intervention occurred in 1.6% of 3,082 IXCHIQ recipients and no placebo recipients. Fourteen IXCHIQ recipients had prolonged (duration at least 30 days) chikungunya-like adverse reactions.

Potential for vertical transmission of vaccine virus and fetal/neonatal adverse reactions. Vertical transmission of wild-type CHIKV from pregnant individuals with viremia at delivery is common and can cause potentially fatal CHIKV disease in neonates. It is not known if the vaccine virus can be vertically transmitted and cause fetal or neonatal adverse reactions. Decisions to administer IXCHIQ during pregnancy should take into consideration the individual's risk of exposure to wild-type CHIKV, gestational age, and risks to the fetus or neonate from vertical transmission of wild-type CHIKV.

Syncope can occur with administration of IXCHIQ. Procedures should be in place to avoid injury from fainting.

IXCHIQ may not protect all individuals who receive the vaccine.

Adverse Reactions

In clinical studies, the most common injection site reaction (>10%) was tenderness (11%). The most common systemic adverse reactions (>10%) were headache (32%), fatigue (29%), myalgia (24%), arthralgia (17%), fever (14%), and nausea (11%).

Use in Specific Populations

Pregnancy

There is a pregnancy registry to monitor outcomes in women exposed to IXCHIQ during pregnancy and it may be reached by contacting OXON Epidemiology at 1-855-417-6214. There are no adequate and well-controlled studies of IXCHIQ in pregnant individuals, and human data available from clinical trials with IXCHIQ are insufficient to establish the presence or absence of vaccine-associated risk during pregnancy.

To report SUSPECTED ADVERSE REACTIONS, contact Valneva at 1-844-349-4276 or VAERS at 1-800-822-7967 or <http://vaers.hhs.gov>.

Please see full Prescribing Information.

References: 1. IXCHIQ. Prescribing information. Valneva USA Inc.; 2023. 2. Chikungunya. World Health Organization. Published December 8, 2022. Accessed March 26, 2024. <https://www.who.int/news-room/fact-sheets/detail/chikungunya> 3. Staples JE, Hills S, Powers A. Chapter 4: Chikungunya. In: Nemhauser J, ed. *CDC Yellow Book 2024*. Centers for Disease Control and Prevention. Updated November 28, 2023. Accessed March 26, 2024. <https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/chikungunya> 4. Puntasecca CJ, King CH, LaBeaud AD. Measuring the global burden of chikungunya and Zika viruses: a systematic review. *PLoS Negl Trop Dis*. 2021;15(3):e0009055. 5. Hucke FIL, Bestehorn-Willmann M, Bugert JJ. Prophylactic strategies to control chikungunya virus infection. *Virus Genes*. 2021;57(2):133-150. 6. Schneider M, Narciso-Abraham M, Hadji S, et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet*. 2023;401(10394):2138-2147.

© 2024 Valneva USA Inc. All rights reserved.

IXCHIQ® is a registered trademark of Valneva Austria GmbH. NOVEMBER 2024 US-IXC-2400115

